AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

Collaboration Across CNS, Immunology, Oncology

 
• By Mandy Jackson
  
AbbVie and ADARx plan to combine their capabilities to develop siRNA medicines (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Scrip